NPPA fixes retail price of 3 formulations including HIV, Oncology drug

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, has fixed the retail price of 3 formulations, including Fixed Dose Combination (FDC) drugs Ivabradine Hydrochloride plus Metoprolol Tartrate Tablet, Darunavir plus Ritonavir Tablet and oncology drug, Trastuzumab Concentrate for solution for Infusion in vials.

The fixed dose combination medication Ivabradine Hydrochloride plus Metoprolol Tartrate Tablet is used in the treatment of angina. It acts by reducing the heart rate and making the heart more efficient at pumping blood throughout the body. The retail price of each film coated tablet containing Ivabradine Hydrochloride, equal to Ivabradine 7.5 mg plus Metoprolol Tartrate 25 mg, marketed by Lupin, has been fixed at Rs 20.68.

The retail price of each HIV medication combination tablet comprising Darunavir IP 800mg and Ritonavir IP 100mg, manufactured by Hetero Labs and marketed by Cipla, has also been set at Rs 190.44.

NPPA has also set the retail price of Roche Pharma's key trademark oncology drug, Trastuzumab Concentrate, which in India is marketed by Cipla. Accordingly, the retail price of each vial containing Trastuzumab 150 mg is Rs15526.97.

Also Read:NPPA fixes retail price of 12 formulations, Details

This price fixation comes following the decisions made by the National Pharmaceutical Pricing Authority at its 87th Authority meeting held on 27th of May 2021, where the Authority discussed retail price fixation of new drugs falling under the purview of Para 2 (u) of DPCO, 2013 and approved the retail prices of new drugs under Para 5 and 15 of the DPCO 2013.

In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (NPPA), fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

The notification further added;

(a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.